Adjuvant Quisinostat in High-Risk Uveal Melanoma
Trial Parameters
Brief Summary
The purpose of this study is to see if giving participants quisinostat will prevent participants' uveal melanoma tumor from spreading. The researchers want to find out the effects that quisinostat has on participants' condition.
Eligibility Criteria
Inclusion Criteria: 1. Primary diagnosis of uveal melanoma (UM) with a lesion of at least 12 mm in largest basal diameter (LBD) as clinically determined by the treating Investigator. Cytologic determination of diagnosis is not required. Size is based on clinical assessment (e.g., by ultrasound or direct ophthalmoscopy) prior to enucleation or radiation therapy. 2. Definitive therapy of the primary UM must have been completed within 183 days of initiating protocol therapy. 3. High-risk (class 2) UM as determined by gene expression profiling (GEP; DecisionDx-UM, Castle Biosciences Inc., Friendswood, TX). 4. No evidence of metastatic disease. 5. Patients aged \>18 years. 6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1. 7. Life expectancy of greater than 3 months. 8. Ability to swallow and retain orally administered medication and no clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome or major resection of the